Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Next Science Ltd

Healthcare AU NXS

0.062AUD
-0.001(1.59%)

Last update at 2025-06-20T05:14:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.060.30
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap16.65M
  • Volume429911
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-9.74150M
  • Revenue TTM22.82M
  • Revenue Per Share TTM0.08
  • Gross Profit TTM 18.44M
  • Diluted EPS TTM-0.06

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -12.68331M -9.34964M -11.91200M -14.35183M -13.74750M
Minority interest - - - - -
Net income -11.83417M -9.35718M -11.83649M -16.52667M -13.74750M
Selling general administrative 5.39M 3.91M 3.14M 8.45M 14.18M
Selling and marketing expenses 10.31M 7.37M 5.65M 0.65M -
Gross profit 9.15M 6.94M 2.92M 3.51M 2.47M
Reconciled depreciation 0.90M 0.79M 0.91M 0.81M -
Ebit -13.54834M -9.59997M -12.52074M -12.25068M -13.81451M
Ebitda -12.65124M -8.80969M -11.81915M -11.68544M -
Depreciation and amortization 0.90M 0.79M 0.70M 0.57M -
Non operating income net other - - - - -
Operating income -13.54834M -9.59997M -12.52074M -12.25068M -13.81452M
Other operating expenses 25.31M 18.56M 15.97M 16.60M 0.04M
Interest expense -0.01588M 1.04M 0.61M 2.10M 0.00000M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.01M 0.13M 0.14M 1.85M 0.07M
Net interest income -0.01588M 0.00004M 0.11M -2.65595M -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.84914M 0.00754M -0.07551M 2.17M -
Total revenue 11.71M 8.95M 3.44M 4.06M 2.84M
Total operating expenses 22.74M 16.55M 15.45M 16.05M 16.66M
Cost of revenue 2.56M 2.01M 0.52M 0.55M 0.37M
Total other income expense net 0.87M 0.25M 0.61M -2.10114M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -12.68331M -9.34964M -15.46612M -20.48505M -13.74750M
Net income applicable to common shares -12.68331M -9.34964M -11.91200M -14.35183M -13.74750M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 9.21M 17.90M 12.46M 13.72M 23.64M
Intangible assets 0.83M 2.39M 2.41M 2.53M 2.33M
Earning assets - - - - -
Other current assets 0.34M - 0.54M 0.48M 0.45M
Total liab 5.77M 5.08M 4.42M 2.95M 4.73M
Total stockholder equity 3.44M 12.82M 8.04M 10.77M 18.91M
Deferred long term liab - - 1.37M 1.49M 1.37M
Other current liab 2.07M - 1.10M 0.77M 0.57M
Common stock 133.93M - 113.53M 102.92M 101.28M
Capital stock - 133.82M 113.53M 102.92M 101.28M
Retained earnings -89.09725M -78.51123M -63.12851M -50.44520M -41.09556M
Other liab - - 0.85M 1.30M 1.38M
Good will - - - - -
Other assets - - 0.04M 1.52M 1.41M
Cash 1.67M 9.24M 5.07M 7.00M 8.10M
Cash and equivalents - - - - -
Total current liabilities 3.22M 3.84M 2.61M 1.54M 3.23M
Current deferred revenue - - 0.27M 0.09M 1.91M
Net debt 0.82M - -3.85365M -6.72483M -7.81358M
Short term debt 0.22M - 0.26M 0.17M 0.17M
Short long term debt - - - - -
Short long term debt total 2.49M - 1.22M 0.28M 0.29M
Other stockholder equity - - -1.90588M -41.70931M -41.27291M
Property plant equipment - - 1.75M 0.92M 1.02M
Total current assets 6.05M 13.96M 8.26M 10.23M 20.25M
Long term investments - - - - -
Net tangible assets - - 6.99M 9.72M 17.95M
Short term investments - 0.04M 0.04M 0.37M 7.24M
Net receivables 3.31M 3.46M 1.74M 0.89M 3.39M
Long term debt - - - - -
Inventory 0.73M 0.72M 0.87M 1.50M 1.07M
Accounts payable 0.93M 1.41M 0.97M 0.52M 0.57M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -41.38735M - -42.36229M -41.70931M -41.27291M
Additional paid in capital - - - - -
Common stock total equity - - - - 131.50M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.26M - 0.04M 0.04M 0.04M
Deferred long term asset charges - - - - -
Non current assets total 3.16M 3.94M 4.20M 3.49M 3.39M
Capital lease obligations - 0.96M 1.22M 0.28M 0.37M
Long term debt total - - 0.96M 0.11M 0.12M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.47572M -0.71676M -0.89172M -2.29521M -
Change to liabilities 0.53M -1.79967M 1.55M -0.21985M 1.50M
Total cashflows from investing activities -0.47572M -0.71676M -0.68680M -1.60802M -0.99277M
Net borrowings -0.25323M -0.21276M -0.22261M -0.13954M 7.74M
Total cash from financing activities 10.25M 1.43M 10.71M 23.68M 17.98M
Change to operating activities -0.38504M -0.05894M 0.00357M -0.73984M -0.09759M
Net income -11.83417M -9.34964M -11.30326M -16.45297M -13.74750M
Change in cash -2.25658M -7.97140M -1.57120M 9.70M 4.61M
Begin period cash flow 7.37M 15.34M 16.91M 7.21M -
End period cash flow 5.11M 7.37M 15.34M 16.91M 10.29M
Total cash from operating activities -10.93707M -8.26435M -11.90664M -12.33156M -12.25291M
Issuance of capital stock 10.89M 1.65M 11.32M 25.54M -
Depreciation 0.90M 0.79M 0.70M 0.57M 0.20M
Other cashflows from investing activities - - - - -
Dividends paid - - - -0.14160M -
Change to inventory 0.56M -0.38936M -0.62952M -0.22309M -0.22882M
Change to account receivables -0.80783M 2.50M -2.09705M -0.57835M -0.69254M
Sale purchase of stock -0.38563M -0.00623M -0.38774M -1.71800M 10.79M
Other cashflows from financing activities -0.25323M -0.21276M -0.22261M 0.07M -0.55669M
Change to netincome 0.10M 0.04M 0.47M 2.94M 0.77M
Capital expenditures 0.48M 0.72M 0.69M 1.61M 0.34M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital - -17.77699M -14.85707M -15.59431M -15.38623M
Stock based compensation - - - - -
Other non cash items 10.94M 8.56M 11.00M 13.55M -
Free cash flow -11.41278M -8.98111M -12.59344M -13.93958M -

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NXS
Next Science Ltd		 -0.001 1.59% 0.06 - 128.21 0.73 3.46 0.56 -11.0461
AFP
AFT Pharmaceuticals Ltd		 -0.05 2.08% 2.35 24.00 20.24 1.23 2.72 1.43 13.69
VLS
Vita Life Sciences Ltd		 0.02 0.91% 2.21 13.75 - 1.52 2.31 1.17 6.89
SNT
Syntara Limited		 -0.004 7.55% 0.05 - 20.45 11.36 5.01 6.32 -2.1607
MVP
Medical Developments International		 - -% 0.57 - 166.67 1.64 1.12 1.22 278.77

Reports Covered

Stock Research & News

View All

Profile

Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides wound management by maintaining a moist wound environment, which is conducive to wound healing; and XPERIENCE for use in cleansing and removal of debris, including microorganisms from wounds. The company was founded in 2012 and is headquartered in Sydney, Australia.

Next Science Ltd

Australia Square, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Ms. Judith Mitchell M.B.A. MD, CEO & Exec. Director NA
Dr. Matthew Franco Myntti Founder & CTO NA
Ms. Jacqueline Butler CA (ICAEW) Chief Financial Officer NA
Mr. Jon Swanson Chief Operating Officer NA
Mr. Michael Morello VP of Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Sec. NA
Mr. Harry Thomas Hall MD, CEO & Director NA
Marc Zimmerman Chief Financial Officer NA
Mr. Robert Bell Senior Vice President of North American Sales NA
Ms. Gillian Maria Nairn AGIA, B.A., BA, L.L.B., L.L.M., LLB, LLM, MAICD Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.